Orchard Therapeutics PLC Valuation

Orchard Therapeutics Investor Information

About 12.0% of the company outstanding shares are owned by corporate insiders. The book value of Orchard Therapeutics was now reported as 3.53. The company recorded a loss per share of 4.1. Orchard Therapeutics PLC had not issued any dividends in recent years. The entity had 1:10 split on the 10th of March 2023. Based on the key indicators related to Orchard Therapeutics' liquidity, profitability, solvency, and operating efficiency, Orchard Therapeutics PLC is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.

Orchard Therapeutics Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Orchard Therapeutics has an asset utilization ratio of 9.98 percent. This suggests that the Company is making $0.0998 for each dollar of assets. An increasing asset utilization means that Orchard Therapeutics PLC is more efficient with each dollar of assets it utilizes for everyday operations.

Orchard Therapeutics Ownership Allocation

The majority of Orchard Therapeutics PLC outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Orchard Therapeutics PLC to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Orchard Therapeutics. Please pay attention to any change in the institutional holdings of Orchard Therapeutics PLC as this could imply that something significant has changed or is about to change at the company.

Orchard Therapeutics Profitability Analysis

The company reported the previous year's revenue of 21.84 M. Net Loss for the year was (72.92 M) with loss before overhead, payroll, taxes, and interest of (76.52 M).

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

If you are still planning to invest in Orchard Therapeutics PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orchard Therapeutics' history and understand the potential risks before investing.